MarketCap
Xenetic Biosciences XBIO
$ 1.87
-1.06%
Facebook
X
Telegram
Xenetic Biosciences P/E Ratio | XBIO
Annual P/E Ratio Xenetic Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.63 | -1 | -1.46 | -0.0868 | -1.73 | -1.37 | -0.337 | -2.55 | -5.35 | -0.645 | -0.234 | -0.174 | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.0868 | -5.35 | -1.38 |
P/E Ratio of other stocks in the Biotechnology industry
| Issuer | P/E Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Институт стволовых клеток человека
ISKJ
|
38.8 | - | - | - |  Russia |
 |
Lyra Therapeutics
LYRA
|
-4.96 | - | - | $ 24.9 M |  USA |
 |
Brickell Biotech
BBI
|
-2 | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Therapeutics
APLT
|
-4.52 | - | - | $ 8.42 M | USA |
 |
ESSA Pharma
EPIX
|
-2.58 | - | - | $ 8.86 M |  Canada |
 |
Generation Bio Co.
GBIO
|
-1.41 | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
-3.12 | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
-13.8 | - | - | $ 5.78 B |  Niderland |
 |
RAPT Therapeutics
RAPT
|
-0.364 | - | - | $ 2.36 B | USA |
 |
Annexon
ANNX
|
-3.72 | $ 4.21 | 4.99 % | $ 653 M | USA |
 |
AbbVie
ABBV
|
220 | $ 291.22 | 1.06 % | $ 515 B | USA |
 |
22nd Century Group
XXII
|
-0.107 | $ 1.56 | -19.17 % | $ 287 K | USA |
 |
Axon Enterprise
AXON
|
245 | $ 313.68 | -18.01 % | $ 24.5 B | USA |
 |
Biogen
BIIB
|
22.7 | $ 248.51 | 1.88 % | $ 36.4 B | USA |
 |
BioLineRx Ltd.
BLRX
|
-2.79 K | $ 1.73 | -2.15 % | $ 4.26 B |  Israel |
 |
Theratechnologies
THTX
|
-9.13 | - | - | $ 83.9 M | Canada |
 |
Exelixis
EXEL
|
15 | $ 69.55 | 1.22 % | $ 18.9 B | USA |
 |
Geron Corporation
GERN
|
-12.7 | $ 0.99 | 3.97 % | $ 660 M | USA |
 |
Gilead Sciences
GILD
|
21.6 | $ 166.9 | -0.4 % | $ 208 B | USA |
 |
Grifols, S.A.
GRFS
|
21.2 | $ 8.46 | -0.12 % | $ 5.75 B |  Spain |
 |
Alnylam Pharmaceuticals
ALNY
|
130 | $ 155.97 | -0.44 % | $ 20.4 B | USA |
 |
InflaRx N.V.
IFRX
|
-1.39 | $ 1.31 | -3.69 % | $ 88.1 M |  Germany |
 |
INmune Bio
INMB
|
-0.614 | $ 1.12 | -4.68 % | $ 27.7 M | USA |
 |
Insmed Incorporated
INSM
|
-24.8 | $ 114.55 | 5.32 % | $ 22.8 B | USA |
 |
Johnson & Johnson
JNJ
|
26.9 | $ 274.89 | 0.95 % | $ 662 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
-0.94 | - | -3.76 % | $ 3.47 M | USA |
 |
Lineage Cell Therapeutics
LCTX
|
-6.63 | $ 1.02 | 3.75 % | $ 235 M | USA |
 |
BioVie
BIVI
|
-0.139 | $ 1.33 | 9.92 % | $ 1.96 M | USA |
 |
Longeveron
LGVN
|
-743 | $ 1.82 | 6.43 % | $ 32 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-2.51 | - | 3.16 % | $ 1.9 M | USA |
 |
TCR2 Therapeutics
TCRR
|
-0.382 | - | - | $ 58.1 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-8.83 | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Mustang Bio
MBIO
|
-2.17 | $ 0.39 | 0.15 % | $ 1.91 M | USA |
 |
TFF Pharmaceuticals
TFFP
|
-0.511 | - | -60.05 % | $ 125 K | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-0.489 | $ 1.63 | 1.87 % | $ 2.68 M | Israel |
 |
Mesoblast Limited
MESO
|
-123 | $ 14.26 | 1.13 % | $ 17.2 B |  Australia |
 |
Mirum Pharmaceuticals
MIRM
|
-233 | $ 93.81 | 0.28 % | $ 4.71 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-18 | - | -15.15 % | $ 60.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
-16.8 | - | - | $ 521 M | USA |
 |
Codexis
CDXS
|
-2.52 | $ 1.09 | 6.37 % | $ 95 M | USA |
 |
MannKind Corporation
MNKD
|
169 | $ 3.91 | 4.0 % | $ 1.2 B | USA |
 |
MediciNova
MNOV
|
5.77 | $ 1.44 | -0.69 % | $ 70.7 M | USA |
 |
Axcella Health
AXLA
|
-0.308 | - | -16.42 % | $ 249 M | USA |
 |
Merck & Co.
MRK
|
17 | $ 146.81 | -0.07 % | $ 367 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
63.3 | - | - | $ 2.02 B | USA |
 |
Tyme Technologies
TYME
|
-1.43 | - | 8.07 % | $ 54 M | USA |
 |
Curis
CRIS
|
-1.25 | $ 0.88 | 3.67 % | $ 11.6 M | USA |